Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 503

1.

Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life.

Henderson MA, Gyorki D, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF.

Ann Surg Oncol. 2019 Sep 12. doi: 10.1245/s10434-019-07810-0. [Epub ahead of print]

PMID:
31515719
2.

Novel Immune Targets in Melanoma-Response.

Edwards J, Batten M, Ferguson A, Palendira U, Wilmott JS, Long GV, Scolyer RA.

Clin Cancer Res. 2019 Sep 1;25(17):5424-5425. doi: 10.1158/1078-0432.CCR-19-1866. No abstract available.

PMID:
31481485
3.

Management of pigmented skin lesions during pregnancy.

Friedman EB, Scolyer RA, Thompson JF.

Aust J Gen Pract. 2019 Sep;48(9):621-624. doi: 10.31128/AJGP-04-19-48952.

4.

Diagnosing melanoma: the method matters.

Rtshiladze MA, Stretch JR, Scolyer RA, Guitera P.

Med J Aust. 2019 Sep;211(5):209-210. doi: 10.5694/mja2.50307. Epub 2019 Aug 14. No abstract available.

PMID:
31414490
5.

Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan.

Lo SN, Hong AM, Haydu LE, Ahmed T, Paton EJ, Steel V, Hruby G, Tran A, Morton RL, Nowak AK, Vardy JL, Drummond KJ, Dhillon HM, Mandel C, Scolyer RA, Middleton MR, Burmeister BH, Thompson JF, Fogarty GB.

Trials. 2019 Aug 5;20(1):477. doi: 10.1186/s13063-019-3555-5.

6.

Management of pigmented skin lesions in childhood and adolescence.

Friedman EB, Scolyer RA, Thompson JF.

Aust J Gen Pract. 2019 Aug;48(8):539-544.

7.

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.

Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV, Mukhopadhyay P, Dummer R, Levesque MP, Jönsson G, Wang X, Yeh I, Wu H, Joseph N, Bastian BC, Long GV, Spillane AJ, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, Scolyer RA.

Nat Commun. 2019 Jul 18;10(1):3163. doi: 10.1038/s41467-019-11107-x.

8.

External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma.

Ipenburg NA, Nieweg OE, Ahmed T, van Doorn R, Scolyer RA, Long GV, Thompson JF, Lo S.

Br J Surg. 2019 Sep;106(10):1319-1326. doi: 10.1002/bjs.11262. Epub 2019 Jul 16.

PMID:
31310333
9.

Isolated Imunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System.

Scolyer RA, Gershenwald JE, Thompson JF.

Am J Surg Pathol. 2019 Oct;43(10):1442-1444. doi: 10.1097/PAS.0000000000001326. No abstract available.

PMID:
31306154
10.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
11.

Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes.

Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, Long GV, Menzies AM.

J Clin Endocrinol Metab. 2019 Jul 2. pii: jc.2019-00423. doi: 10.1210/jc.2019-00423. [Epub ahead of print]

PMID:
31265074
12.

Improving diagnostic accuracy for suspicious melanocytic skin lesions: New Australian melanoma clinical practice guidelines stress the importance of clinician/pathologist communication.

Scolyer RA, Soyer HP, Kelly JW, James C, McLean CA, Coventry BJ, Ferguson PM, Rawson RV, Mar VJ, de Menezes SL, Fishburn P, Stretch JR, Lee S, Thompson JF.

Aust J Gen Pract. 2019 Jun;48(6):357-362.

13.

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.

Long GV, Saw RPM, Lo S, Nieweg OE, Shannon KF, Gonzalez M, Guminski A, Lee JH, Lee H, Ferguson PM, Rawson RV, Wilmott JS, Thompson JF, Kefford RF, Ch'ng S, Stretch JR, Emmett L, Kapoor R, Rizos H, Spillane AJ, Scolyer RA, Menzies AM.

Lancet Oncol. 2019 Jul;20(7):961-971. doi: 10.1016/S1470-2045(19)30331-6. Epub 2019 Jun 3.

PMID:
31171444
14.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, Ter Meulen S, Koenen AM, Bosch LJW, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, Blank CU.

Lancet Oncol. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31.

PMID:
31160251
15.

LNK suppresses interferon signaling in melanoma.

Ding LW, Sun QY, Edwards JJ, Fernández LT, Ran XB, Zhou SQ, Scolyer RA, Wilmott JS, Thompson JF, Doan N, Said JW, Venkatachalam N, Xiao JF, Loh XY, Pein M, Xu L, Mullins DW, Yang H, Lin DC, Koeffler HP.

Nat Commun. 2019 May 20;10(1):2230. doi: 10.1038/s41467-019-09711-y.

16.

Estimated risk of progression of lentigo maligna to lentigo maligna melanoma.

Menzies SW, Liyanarachchi S, Coates E, Smith A, Cooke-Yarborough C, Lo S, Armstrong B, Scolyer RA, Guitera P.

Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000619. [Epub ahead of print]

PMID:
31095041
17.

Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer.

Hong AM, Ferguson P, Dodds T, Jones D, Li M, Yang J, Scolyer RA.

Oral Oncol. 2019 May;92:33-39. doi: 10.1016/j.oraloncology.2019.03.012. Epub 2019 Mar 18.

PMID:
31010620
18.

CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function.

Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall VLJ, Liu C, Bettington ML, Takeda K, Long GV, Scolyer RA, Lan R, Siemers N, Korman A, Teng MWL, Johnston RJ, Dougall WC, Smyth MJ.

Cancer Immunol Res. 2019 Apr;7(4):559-571. doi: 10.1158/2326-6066.CIR-18-0637. Epub 2019 Mar 20.

PMID:
30894377
19.

Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system.

Haydu LE, Thompson JF, Scolyer RA, Gershenwald JE.

Eur J Cancer. 2019 May;112:9-11. doi: 10.1016/j.ejca.2019.01.103. Epub 2019 Mar 15. No abstract available.

PMID:
30884440
20.

Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers.

Dessinioti C, Dimou N, Geller AC, Stergiopoulou A, Lo S, Keim U, Gershenwald JE, Haydu LE, Ribero S, Quaglino P, Puig S, Malvehy J, Kandolf-Sekulovic L, Radevic T, Kaufmann R, Meister L, Nagore E, Traves V, Champsas GG, Plaka M, Dreno B, Varey E, Ramirez DM, Dummer R, Mangana J, Hauschild A, Egberts F, Peris K, Del Regno L, Forsea AM, Zurac SA, Vieira R, Brinca A, Zalaudek I, Deinlein T, Linos E, Evangelou E, Thompson JF, Scolyer RA, Garbe C, Stratigos AJ.

J Natl Cancer Inst. 2019 Mar 13. pii: djz034. doi: 10.1093/jnci/djz034. [Epub ahead of print]

PMID:
30863861
21.

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.

Lee JH, Saw RP, Thompson JF, Lo S, Spillane AJ, Shannon KF, Stretch JR, Howle J, Menzies AM, Carlino MS, Kefford RF, Long GV, Scolyer RA, Rizos H.

Ann Oncol. 2019 May 1;30(5):815-822. doi: 10.1093/annonc/mdz075.

22.

Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells.

Qutob N, Masuho I, Alon M, Emmanuel R, Cohen I, Di Pizio A, Madore J, Elkahloun A, Ziv T, Levy R, Gartner JJ, Hill VK, Lin JC, Hevroni Y, Greenberg P, Brodezki A, Rosenberg SA, Kosloff M, Hayward NK, Admon A, Niv MY, Scolyer RA, Martemyanov KA, Samuels Y.

Sci Rep. 2019 Mar 9;9(1):4523. doi: 10.1038/s41598-018-37932-6.

23.

Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas.

Quek C, Rawson RV, Ferguson PM, Shang P, Silva I, Saw RPM, Shannon K, Thompson JF, Hayward NK, Long GV, Mann GJ, Scolyer RA, Wilmott JS.

Oncotarget. 2019 Jan 29;10(9):930-941. doi: 10.18632/oncotarget.26584. eCollection 2019 Jan 29.

24.

Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials.

Edwards J, Tasker A, Pires da Silva I, Quek C, Batten M, Ferguson A, Allen R, Allanson B, Saw RPM, Thompson JF, Menzies AM, Palendira U, Wilmott JS, Long GV, Scolyer RA.

Clin Cancer Res. 2019 Jun 1;25(11):3247-3258. doi: 10.1158/1078-0432.CCR-18-4011. Epub 2019 Feb 18.

PMID:
30777877
25.

Molecular Genomic Profiling of Melanocytic Nevi.

Colebatch AJ, Ferguson P, Newell F, Kazakoff SH, Witkowski T, Dobrovic A, Johansson PA, Saw RPM, Stretch JR, McArthur GA, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Waddell N, Scolyer RA, Wilmott JS.

J Invest Dermatol. 2019 Aug;139(8):1762-1768. doi: 10.1016/j.jid.2018.12.033. Epub 2019 Feb 14.

PMID:
30772300
26.

Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck.

Thompson JF, Lo S, Scolyer RA.

JAMA Dermatol. 2019 Apr 1;155(4):502. doi: 10.1001/jamadermatol.2018.5742. No abstract available.

PMID:
30758490
27.

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.

Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RPM, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Silva IPD, Batten M, Scolyer RA, Long GV, Wilmott JS.

Cancer Cell. 2019 Feb 11;35(2):238-255.e6. doi: 10.1016/j.ccell.2019.01.003.

PMID:
30753825
28.

Author Correction: Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin.

Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, McBain N, Wagner T, Edwards J, McConville R, Wilmott JS, Scolyer RA, Tüting T, Palendira U, Gyorki D, Mueller SN, Huntington ND, Bedoui S, Hölzel M, Mackay LK, Waithman J, Gebhardt T.

Nature. 2019 Feb;566(7745):E10. doi: 10.1038/s41586-019-0958-0.

PMID:
30742076
29.

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients.

Lee H, Quek C, Silva I, Tasker A, Batten M, Rizos H, Lim SY, Nur Gide T, Shang P, Attrill GH, Madore J, Edwards J, Carlino MS, Guminski A, Saw RPM, Thompson JF, Ferguson PM, Palendira U, Menzies AM, Long GV, Scolyer RA, Wilmott JS.

Oncoimmunology. 2018 Oct 31;8(2):e1537581. doi: 10.1080/2162402X.2018.1537581. eCollection 2019.

PMID:
30713793
30.

The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.

Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, Ollila DW, Frank JS, Thomas NE, Googe PB, Ezzell AJ, Collichio FA, Lee CB, Earp HS, Sharpless NE, Hugo W, Wilmott JS, Quek C, Waddell N, Johansson PA, Thompson JF, Hayward NK, Mann GJ, Lo RS, Johnson DB, Scolyer RA, Hayes DN, Moschos SJ.

Front Oncol. 2019 Jan 4;8:584. doi: 10.3389/fonc.2018.00584. eCollection 2018.

31.

Staging of Cutaneous Melanoma: Is There Room for Further Improvement?

Ferguson PM, Gershenwald JE, Scolyer RA.

JAMA Netw Open. 2018 May 18;1(1):e180086. doi: 10.1001/jamanetworkopen.2018.0086. No abstract available.

PMID:
30646045
32.

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.

Pires da Silva I, Wang KYX, Wilmott JS, Holst J, Carlino MS, Park JJ, Quek C, Wongchenko M, Yan Y, Mann G, Johnson DB, McQuade JL, Rai R, Kefford RF, Rizos H, Scolyer RA, Yang JYH, Long GV, Menzies AM.

Clin Cancer Res. 2019 Feb 15;25(4):1272-1279. doi: 10.1158/1078-0432.CCR-18-1680. Epub 2019 Jan 10.

PMID:
30630828
33.

Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin.

Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, McBain N, Wagner T, Edwards J, McConville R, Wilmott JS, Scolyer RA, Tüting T, Palendira U, Gyorki D, Mueller SN, Huntington ND, Bedoui S, Hölzel M, Mackay LK, Waithman J, Gebhardt T.

Nature. 2019 Jan;565(7739):366-371. doi: 10.1038/s41586-018-0812-9. Epub 2018 Dec 31. Erratum in: Nature. 2019 Feb;566(7745):E10.

PMID:
30598548
34.

Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment.

Gide TN, Allanson BM, Menzies AM, Ferguson PM, Madore J, Saw RPM, Thompson JF, Long GV, Wilmott JS, Scolyer RA.

Histopathology. 2019 May;74(6):817-828. doi: 10.1111/his.13814.

PMID:
30589949
35.

Subungual Melanoma of the Hand.

Chakera AH, Quinn MJ, Lo S, Drummond M, Haydu LE, Bond JS, Stretch JR, Saw RPM, Lee KJ, McCarthy WH, Scolyer RA, Thompson JF.

Ann Surg Oncol. 2019 Apr;26(4):1035-1043. doi: 10.1245/s10434-018-07094-w. Epub 2018 Dec 18.

PMID:
30565042
36.

RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes.

Guo D, Lui GYL, Lai SL, Wilmott JS, Tikoo S, Jackett LA, Quek C, Brown DL, Sharp DM, Kwan RYQ, Chacon D, Wong JH, Beck D, van Geldermalsen M, Holst J, Thompson JF, Mann GJ, Scolyer RA, Stow JL, Weninger W, Haass NK, Beaumont KA.

Int J Cancer. 2019 Jun 15;144(12):3070-3085. doi: 10.1002/ijc.32064. Epub 2019 Jan 3.

PMID:
30556600
37.

Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases.

Dodds TJ, Wilmott JS, Jackett LA, Lo SN, Long GV, Thompson JF, Scolyer RA.

Pathology. 2019 Jan;51(1):39-45. doi: 10.1016/j.pathol.2018.09.060. Epub 2018 Nov 26.

PMID:
30497801
38.

ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas.

Thompson JF, Scolyer RA, Lo SN.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):918-919. doi: 10.1245/s10434-018-7014-4. Epub 2018 Nov 9. No abstract available.

PMID:
30414034
39.

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy.

Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, Breen EJ, Yang JYH, Ghazanfar S, Kefford RF, Scolyer RA, Long GV, Rizos H.

Clin Cancer Res. 2019 Mar 1;25(5):1557-1563. doi: 10.1158/1078-0432.CCR-18-2795. Epub 2018 Nov 8.

PMID:
30409824
40.

Epigenetic profiling for the molecular classification of metastatic brain tumors.

Orozco JIJ, Knijnenburg TA, Manughian-Peter AO, Salomon MP, Barkhoudarian G, Jalas JR, Wilmott JS, Hothi P, Wang X, Takasumi Y, Buckland ME, Thompson JF, Long GV, Cobbs CS, Shmulevich I, Kelly DF, Scolyer RA, Hoon DSB, Marzese DM.

Nat Commun. 2018 Nov 6;9(1):4627. doi: 10.1038/s41467-018-06715-y.

41.

Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features.

Salomon MP, Orozco JIJ, Wilmott JS, Hothi P, Manughian-Peter AO, Cobbs CS, Scolyer RA, Hoon DSB, Marzese DM.

Sci Data. 2018 Nov 6;5:180245. doi: 10.1038/sdata.2018.245.

42.

Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens.

Friedman EB, Dodds TJ, Lo S, Ferguson PM, Beck M, Saw RPM, Stretch JR, Lee KK, Nieweg OE, Spillane AJ, Scolyer RA, Thompson JF.

Ann Surg Oncol. 2019 Jan;26(1):25-32. doi: 10.1245/s10434-018-6858-y. Epub 2018 Oct 16.

PMID:
30327975
43.

The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population-based data on diagnosis and management.

Guitera P, Collgros H, Madronio CM, Goumas C, Mann GJ, Watts CG, Pereira AR, Armstrong BK, Drummond M, Morton RL, Scolyer RA, Menzies SW, Thompson JF, Cust AE.

Australas J Dermatol. 2019 May;60(2):118-125. doi: 10.1111/ajd.12928. Epub 2018 Oct 9.

PMID:
30302753
44.

Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas.

Friedman EB, Moncrieff MD, Lo S, Scolyer RA, Thompson JF.

Australas J Dermatol. 2019 Feb;60(1):75-76. doi: 10.1111/ajd.12942. Epub 2018 Oct 7. No abstract available.

PMID:
30294907
45.

A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide.

Minocha R, Martin AJ, Chen AC, Scolyer RA, Lyons JG, McKenzie CA, Madore J, Halliday GM, Damian DL.

J Invest Dermatol. 2019 Feb;139(2):467-469. doi: 10.1016/j.jid.2018.08.018. Epub 2018 Sep 20. No abstract available.

PMID:
30244097
46.

Comment on "Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma".

Lo SN, Stodell MD, Scolyer RA, Thompson JF.

J Am Acad Dermatol. 2019 Jan;80(1):e21-e22. doi: 10.1016/j.jaad.2018.07.068. Epub 2018 Sep 15. No abstract available.

PMID:
30227195
47.

bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arrays.

Wang KYX, Menzies AM, Silva IP, Wilmott JS, Yan Y, Wongchenko M, Kefford RF, Scolyer RA, Long GV, Tarr G, Mueller S, Yang JYH.

Bioinformatics. 2019 Apr 15;35(8):1350-1357. doi: 10.1093/bioinformatics/bty783.

PMID:
30215668
48.

Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts.

Isaksson K, Nielsen K, Mikiver R, Nieweg OE, Scolyer RA, Thompson JF, Ingvar C.

J Surg Oncol. 2018 Sep;118(4):599-605. doi: 10.1002/jso.25208. Epub 2018 Sep 9.

PMID:
30196533
49.

Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project.

Wilmott JS, Hayward NK, Mann GJ, Scolyer RA.

Melanoma Manag. 2017 Sep;4(3):147-149. doi: 10.2217/mmt-2017-0008. Epub 2017 Jul 26. No abstract available.

50.

Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility.

Wilmott JS, Johansson PA, Newell F, Waddell N, Ferguson P, Quek C, Patch AM, Nones K, Shang P, Pritchard AL, Kazakoff S, Holmes O, Leonard C, Wood S, Xu Q, Saw RPM, Spillane AJ, Stretch JR, Shannon KF, Kefford RF, Menzies AM, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA.

Int J Cancer. 2019 Mar 1;144(5):1049-1060. doi: 10.1002/ijc.31791. Epub 2018 Nov 21.

PMID:
30178487

Supplemental Content

Loading ...
Support Center